EMA gains more power to monitor medicines

The role of the European Medicines Agency (EMA) is being reinforced, as the EU is increasing its powers to monitor drug development in times of crisis. ”A stronger EMA means that we can count on a coordinated EU response in mitigating and preventing medicine and medical devices shortages,” EU officials say.

Soon, the European Medicines Agency (EMA) will have more power to oversee European drugmaking.

This was evident on Thursday, after EU member countries and the European Parliament agreed to give the agency additional powers to ensure the union’s crisis preparedness, as reported by Agence Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs